GlaxoSmithKline plc, a healthcare company, researches and develops products in the areas of pharmaceuticals, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The company has a commercial presence in approximately 150 markets, a network of 86 manufacturing sites in 36 countries and research and development centers in the U.K., USA, Spain, Belgium and China. Segments The company operates in the following segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Pharmaceuticals: The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Vaccines: The Vaccines segment produces paediatric and adult vaccines against a range of infectious diseases. In 2013, the company distributed approximately 860 million doses to 170 countries, of which approximately 80% were supplied to developing countries. Consumer Healthcare: The company develops and markets a range of consumer healthcare products. It has brands in four main categories: Total Wellness, Oral Care, Nutrition and Skin Health. These include brands, such as Sensodyne, Panadol and Horlicks. Research and Development In 2013, the company spent £3.9 billion in total, in search to develop innovative medicines, vaccines and consumer products. Competition The company’s main consumer healthcare competitors include Colgate-Palmolive, Johnson & Johnson, Procter & Gamble, Reckitt Benckiser, Unilever, Pfizer and Novartis. Its principal research-based pharmaceutical and vaccines competitors include AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, NovoNordisk, Pfizer, Roche Holdings, Sanofi and Takeda. Significant Events In April 2014, GlaxoSmithkline Consumer Healthcare Ltd. announced that GSK Plc and Novartis AG have entered into an agreement to create Consumer Healthcare Joint Venture to hold GSK's Consumer Healthcare business and Novartis OTC Consumer Healthcare business. In June 2014, Adaptimmune entered into a strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise Adaptimmune's NY-ESO-1 clinical cancer programme. In June 2014, GlaxoSmithKline and ViV Healthcare has teamed up with Janssen R&D Ireland to develop and commercialize a single-tablet dose of an HIV treatment. In June 2014, Cepheid announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals Inc. and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. History GlaxoSmithKline plc was founded in 1935.
glaxosmithkline plc-spon adr
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
|3M Co||$146.69 USD||-0.15|
|Amgen Inc||$144.01 USD||+1.99|
|AstraZeneca PLC||4,579 GBp||+42.00|
|Bayer AG||€112.33 EUR||+0.32|
|Novo Nordisk A/S||kr281.70 DKK||+0.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.